Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)
Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)
Not yet recruiting · NCT07820995 · Registry updated 2026-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Fibrosis, IgA glomerulonephritis, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Not yet recruiting | Phase 4 | 2026-09-21 | NCT07820995 |
6 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Endeavor Health | 38 |
| Icahn School of Medicine at Mount Sinai | 256 |
| Novartis | 114 |
| University of Illinois at Chicago | 211 |
| University of Michigan | 394 |
| University of North Carolina, Chapel Hill | 249 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Illinois Chicago | Chicago | United States | 41 |